Chimeric Enzyme-Transferrin Conjugates for Blood-Brain Barrier Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for lysosomal storage diseases, such as late-onset Tay-Sachs, face challenges in delivering therapeutic enzymes across the blood-brain barrier due to the barrier's restrictive permeability, limiting the effectiveness of enzyme replacement therapy for neurological manifestations.
Innovation Solution
Development of chimeric proteins comprising a polypeptide hormone, such as G-CSF or leptin, covalently linked to a therapeutic enzyme, which can cross the blood-brain barrier and transport the enzyme to lysosomes within the central nervous system, utilizing receptor-mediated transport systems to facilitate delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional enzyme replacement therapy is used, then the therapeutic enzyme can be delivered to peripheral tissues, but the enzyme cannot effectively cross the blood-brain barrier to reach the central nervous system
Solution Approach 1:
The patent uses transferrin as an intermediary carrier molecule that naturally crosses the blood-brain barrier via receptor-mediated transcytosis. The therapeutic enzyme is conjugated to transferrin, allowing it to 'hitchhike' across the barrier. The transferrin-enzyme conjugate binds to transferrin receptors on the blood-brain barrier endothelial cells, is internalized, and transported into the brain parenchyma, thereby overcoming the barrier's restrictive permeability to large hydrophilic molecules.
Solution Approach 2:
The invention creates a composite therapeutic agent by chemically conjugating the therapeutic enzyme (such as beta-hexosaminidase A for Tay-Sachs disease) with the carrier protein transferrin. This composite structure combines the barrier-crossing capability of transferrin with the therapeutic function of the enzyme, enabling the enzyme to reach previously inaccessible target tissues in the central nervous system.
2Reliability
If the blood-brain barrier permeability is increased to allow enzyme entry, then the therapeutic enzyme can reach the brain, but the selective protection function of the barrier is compromised
Solution Approach 1:
The patent exploits the localized presence of transferrin receptors on the blood-brain barrier endothelial cells. Rather than attempting to increase general barrier permeability, the solution targets the specific local property of transferrin receptor-mediated transport. The therapeutic enzyme-conjugate utilizes this localized transport mechanism to cross the barrier selectively, maintaining the barrier's protective function for other substances while enabling targeted delivery of the therapeutic agent.
3Ease of operation
If a Trojan horse approach is used with known carriers like transferrin or insulin, then the therapeutic molecule can cross the barrier, but the delivery system becomes complex and may have limited specificity
Solution Approach 1:
The patent employs transferrin as a universal carrier platform that can conjugate with various therapeutic enzymes through its thiol groups. This multi-functional approach allows the same carrier molecule to deliver different therapeutic enzymes (e.g., beta-hexosaminidase A, alpha-L-iduronidase) across the blood-brain barrier, simplifying the overall delivery strategy while maintaining high efficiency. The conjugation chemistry is standardized, reducing complexity despite the diversity of therapeutic agents.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The chimeric proteins effectively deliver therapeutic enzymes across the blood-brain barrier, enabling targeted enzyme replacement and potential therapeutic benefits for lysosomal storage diseases by ensuring the enzyme reaches the affected cells within the brain, thereby addressing the limitations of existing delivery methods.
Implementation Method 1
utilizing receptor-mediated transport systems to facilitate delivery
Data Source
AI summary
The present invention relates in general to the field of enzyme replacement therapy, and specifically to chimeric proteins including protein hormone-therapeutic protein conjugates and fusion proteins, wherein the protein hormone is selected from a protein hormone which is able to cross the blood brain barrier, for the treatment of lysosomal storage diseases, compositions of the same and to methods of use thereof.